Harmonizome 3.0

cellular retinoic acid binding protein 1

This gene encodes a specific binding protein for a vitamin A family member and is thought to play an important role in retinoic acid-mediated differentiation and proliferation processes. It is structurally similar to the cellular retinol-binding proteins, but binds only retinoic acid at specific sites within the nucleus, which may contribute to vitamin A-directed differentiation in epithelial tissue. [provided by RefSeq, Jul 2008]

stimulated by retinoic acid 6

The protein encoded by this gene is a membrane protein involved in the metabolism of retinol. The encoded protein acts as a receptor for retinol/retinol binding protein complexes. This protein removes the retinol from the complex and transports it across the cell membrane. Defects in this gene are a cause of syndromic microphthalmia type 9 (MCOPS9). Several transcript variants encoding a few different isoforms have been found for this gene. [provided by RefSeq, Dec 2008]

retinoic acid receptor, alpha

This gene represents a nuclear retinoic acid receptor. The encoded protein, retinoic acid receptor alpha, regulates transcription in a ligand-dependent manner. This gene has been implicated in regulation of development, differentiation, apoptosis, granulopoeisis, and transcription of clock genes. Translocations between this locus and several other loci have been associated with acute promyelocytic leukemia. Alternatively spliced transcript variants have been found for this locus.[provided by RefSeq, Sep 2010]

retinoic acid receptor, beta

This gene encodes retinoic acid receptor beta, a member of the thyroid-steroid hormone receptor superfamily of nuclear transcriptional regulators. This receptor localizes to the cytoplasm and to subnuclear compartments. It binds retinoic acid, the biologically active form of vitamin A which mediates cellular signalling in embryonic morphogenesis, cell growth and differentiation. It is thought that this protein limits growth of many cell types by regulating gene expression. The gene was first identified in a hepatocellular carcinoma where it flanks a hepatitis B virus integration site. Alternate promoter usage and differential splicing result in multiple transcript variants. [provided by RefSeq, Mar 2014]

retinoic acid receptor, gamma

This gene encodes a retinoic acid receptor that belongs to the nuclear hormone receptor family. Retinoic acid receptors (RARs) act as ligand-dependent transcriptional regulators. When bound to ligands, RARs activate transcription by binding as heterodimers to the retinoic acid response elements (RARE) found in the promoter regions of the target genes. In their unbound form, RARs repress transcription of their target genes. RARs are involved in various biological processes, including limb bud development, skeletal growth, and matrix homeostasis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]

cellular retinoic acid binding protein 2

This gene encodes a member of the retinoic acid (RA, a form of vitamin A) binding protein family and lipocalin/cytosolic fatty-acid binding protein family. The protein is a cytosol-to-nuclear shuttling protein, which facilitates RA binding to its cognate receptor complex and transfer to the nucleus. It is involved in the retinoid signaling pathway, and is associated with increased circulating low-density lipoprotein cholesterol. Alternatively spliced transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Dec 2010]

retinoic acid induced 1

This gene is located within the Smith-Magenis syndrome region on chromosome 17. It is highly similar to its mouse counterpart and is expressed at high levels mainly in neuronal tissues. The protein encoded by this gene includes a polymorphic polyglutamine tract in the N-terminal domain. Expression of the mouse counterpart in neurons is induced by retinoic acid. This gene is associated with both the severity of the phenotype and the response to medication in schizophrenic patients. [provided by RefSeq, Jul 2008]

retinoic acid receptor responder (tazarotene induced) 2

This gene encodes a secreted chemotactic protein that initiates chemotaxis via the ChemR23 G protein-coupled seven-transmembrane domain ligand. Expression of this gene is upregulated by the synthetic retinoid tazarotene and occurs in a wide variety of tissues. The active protein has several roles, including that as an adipokine and as an antimicrobial protein with activity against bacteria and fungi. [provided by RefSeq, Nov 2014]

retinoic acid receptor responder (tazarotene induced) 3

Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator. [provided by RefSeq, Jul 2008]

retinoic acid receptor responder (tazarotene induced) 1

This gene was identified as a retinoid acid (RA) receptor-responsive gene. It encodes a type 1 membrane protein. The expression of this gene is upregulated by tazarotene as well as by retinoic acid receptors. The expression of this gene is found to be downregulated in prostate cancer, which is caused by the methylation of its promoter and CpG island. Alternatively spliced transcript variant encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

retinoic acid receptor responder protein 2 pseudogene

all-trans retinoic acid-induced differentiation factor

This gene is thought to be involved in apoptosis, and may also be involved in hematopoietic development and differentiation. The use of alternative splice sites and promotors result in multiple transcript variants encoding different isoforms.[provided by RefSeq, Dec 2009]

stimulated by retinoic acid 8

This gene encodes a retinoic acid-responsive protein. A homologous protein in mouse has been shown to be involved in the regulation of meiotic initiation in both spermatogenesis and oogenesis, though feature differences between the mouse and human proteins suggest that these homologs are not entirely functionally equivalent. It is thought that this gene may play a role in spermatogenesis in humans. [provided by RefSeq, Nov 2010]

bone morphogenetic protein/retinoic acid inducible neural-specific 3

This gene is overexpressed in pituitary tumors but is underexpressed in tongue squamous cell carcinomas, ulcerative colitis, and peri-implantitis. Polymorphisms that increase expression of this gene have been shown to increase vascular inflammation, and an association of this gene with myocardial infarction has been demonstrated. Finally, hypermethylation of this gene may find usefulness as a biomarker for gastric cancer. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]

bone morphogenetic protein/retinoic acid inducible neural-specific 2

Predicted to be involved in cellular response to retinoic acid; central nervous system neuron differentiation; and negative regulation of mitotic cell cycle. Predicted to act upstream of or within locomotion and nervous system development. Predicted to be located in extracellular region. Predicted to be active in cytoplasm; dendrite; and neuronal cell body. Implicated in oral squamous cell carcinoma. [provided by Alliance of Genome Resources, Mar 2025]

bone morphogenetic protein/retinoic acid inducible neural-specific 1

This gene is located within a chromosomal region that shows loss of heterozygosity in some bladder cancers. It contains a 5' CpG island that may be a frequent target of hypermethylation, and it may undergo hypermethylation-based silencing in some bladder cancers. [provided by RefSeq, Jul 2008]

retinoic acid early transcript 1K pseudogene

retinoic acid early transcript 1M pseudogene

retinoic acid induced 2

Retinoic acid plays a critical role in development, cellular growth, and differentiation. The specific function of this retinoic acid-induced gene has not yet been determined but it may play a role in development. The chromosomal location of this gene designates it to be a candidate for diseases such as Nance-Horan syndrome, sensorineural deafness, non-specific X-linked cognitive disability, oral-facial-digital syndrome, and Fried syndrome. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2010]

stimulated by retinoic acid 13

Enables DNA binding activity. Contributes to double-stranded DNA binding activity. Involved in interstrand cross-link repair; replication fork processing; and resolution of meiotic recombination intermediates. Part of chromosome and nucleus. [provided by Alliance of Genome Resources, Mar 2025]

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 8

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 2

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 1

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 4

retinoic acid early transcript 1E

This gene belong to the RAET1 family, which consists of major histocompatibility complex (MHC) class I-related genes located in a cluster on chromosome 6q24.2-q25.3. This and RAET1G protein differ from other RAET1 proteins in that they have type I membrane-spanning sequences at their C termini rather than glycosylphosphatidylinositol anchor sequences. This protein functions as a ligand for NKG2D receptor, which is expressed on the surface of several types of immune cells, and is involved in innate and adaptive immune responses. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Aug 2011]

retinoic acid early transcript 1G

This gene encodes a member of the major histocompatibility complex (MHC) class I family of proteins. Although the encoded protein includes C-terminal transmembrane and cytoplasmic domains, proteolytic processing results in the removal of these domains and subsequent tethering to the plasma membrane by a glycosylphosphatidylinositol (GPI)-anchor. The encoded protein is one of several related ligands of the natural killer group 2, member D (NKG2D) receptor, which functions as an activating receptor in innate and adaptive immunity. This gene is present in a gene cluster on chromosome 6. [provided by RefSeq, Jul 2015]

retinoic acid early transcript 1F pseudogene

retinoic acid early transcript 1L

RAET1L belongs to the RAET1 family of major histocompatibility complex (MHC) class I-related genes, which are located within a 180-kb cluster on chromosome 6q24.2-q25.3. The REAT1 genes encode glycoproteins that contain extracellular alpha-1 and alpha-2 domains, but they lack the membrane proximal Ig-like alpha-3 domain. Most RAET1 glycoproteins are anchored to the membrane via glycosylphosphatidylinositol (GPI) linkage (Radosavljevic et al., 2002 [PubMed 11827464]).[supplied by OMIM, Mar 2008]

retinoic acid induced 14

Predicted to enable actin binding activity. Predicted to be involved in cell differentiation and spermatogenesis. Located in cytosol; fibrillar center; and nucleoplasm. [provided by Alliance of Genome Resources, Mar 2025]

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical 13-cis-12-(3'-carboxyphenyl)retinoic acid from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical 4-(1H-imidazol-1-yl)retinoic acid from the curated CTD Gene-Chemical Interactions dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term retinoic in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From GO Biological Process Annotations 2015

genes participating in the 9-cis-retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the response to retinoic acid biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the 9-cis-retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid catabolic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the cellular response to retinoic acid biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid 4-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid-responsive element binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid receptor binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the 9-cis retinoic acid receptor activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid receptor activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From Guide to Pharmacology Chemical Ligands of Receptors

receptors of the all-trans-4-oxo-retinoic acid ligand (chemical) from the curated Guide to Pharmacology Chemical Ligands of Receptors dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the All-trans-retinoic acid metabolite from the curated HMDB Metabolites of Enzymes dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the 9-cis-Retinoic acid metabolite from the curated HMDB Metabolites of Enzymes dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the 13-cis-Retinoic acid metabolite from the curated HMDB Metabolites of Enzymes dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid receptor responder protein 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid receptor responder protein 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid receptor protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid-induced protein 2/sine oculis-binding protein homologue protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid induced 16-like protein protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Stimulated by retinoic acid gene 6 protein protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From Phosphosite Textmining Biological Term Annotations

proteins co-occuring with the biological term retinoic in abstracts of publications describing phosphosites from the Phosphosite Textmining Biological Term Annotations dataset.

From PID Pathways

proteins participating in the Retinoic acid receptors-mediated signaling pathway from the PID Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by Retinoic Acid pathway from the Reactome Pathways dataset.

From DisGeNET Gene-Disease Associations

genes associated with the disease Retinoic Acid Syndrome in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset.

From GO Biological Process Annotations 2023

genes participating in the negative regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the cellular response to retinoic acid biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the response to retinoic acid biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the retinoic acid catabolic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the negative regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the positive regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the 9-cis-retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the 9-cis-retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the nuclear retinoic acid receptor binding molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the retinoic acid binding molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the retinoic acid 4-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the all-trans retinoic acid 18-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the retinoic acid-responsive element binding molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the all-trans retinoic acid 3,4-desaturase activity molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From MW Enzyme Metabolite Associations

interacting proteins for Retinoic acid metabolite from the MW Gene Metabolite Associations dataset.

From MW Enzyme Metabolite Associations

interacting proteins for 9-cis-Retinoic acid metabolite from the MW Gene Metabolite Associations dataset.

From WikiPathways Pathways 2024

proteins participating in the 4 hydroxytamoxifen dexamethasone and retinoic acids regulation of p27 expression pathway from the WikiPathways Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by Retinoic Acid pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation pathway from the Reactome Pathways 2024 dataset.

From GO Biological Process Annotations 2025

genes participating in the negative regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the cellular response to retinoic acid biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the response to retinoic acid biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid catabolic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the negative regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the positive regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the 9-cis-retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the 9-cis-retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the nuclear retinoic acid receptor binding molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the retinoic acid binding molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the retinoic acid 4-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the all-trans retinoic acid 18-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the retinoic acid-responsive element binding molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the all-trans retinoic acid 3,4-desaturase activity molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_H4 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A498 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_hTERT-HPNE drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_KATO III drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_AN3 CA drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_LS 180 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SK-MEL-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A-172 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_RPMI-7951 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW 900 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_CFPAC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H460 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_Panc 03.27 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HT-29 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HEC-1-A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A549 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_AsPC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HepG2/C3A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW1417 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_BT-474 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW 1271 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_C32 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_RKO drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW480 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW 1088 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_COLO 205 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SNU-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_J82 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_CHP-212 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SHP-77 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A-427 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SNU-423 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HOP62 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_PANC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_C-33 A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_LOX-IMVI drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_LoVo drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HCT15 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW48 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From DGIdb Drug Targets 2026

interacting proteins for the ALL-TRANS-4-OXO-RETINOIC ACID drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the RETINOIC ACID AGENT drug from theDGIdb Drug Targets 2026 dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles

genes with high or low copy number in HS 766T relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles

genes with high or low expression in HS 766T relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles

genes mutated in the HS 766T cell line from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles dataset.

From TISSUES Text-mining Tissue Protein Expression Evidence Scores

proteins co-occuring with the tissue hs-766t cell in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores dataset.

From Sanger Dependency Map Cancer Cell Line Proteomics

proteins associated with the cell line Hs-766T from the Sanger Dependency Map Cancer Cell Line Proteomics dataset.

From TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025

proteins co-occuring with the tissue HS-766T cell in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vitamin K4_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Talc_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dihydroartemisinin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Encorafenib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Idarubicin (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the TAK-733_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trametinib (DMSO_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Demeclocycline_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the XRK3F2_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Penfluridol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Relugolix_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AT7519_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bimiralisib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Binimetinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Raltitrexed_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nevirapine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Paclitaxel_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trametinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sulfisoxazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD-7648_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tranilast_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Terfenadine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tetracycline (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mifepristone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Verteporfin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the (R)-Verapamil (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ULK-101_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lenalidomide (hemihydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rosiglitazone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cobimetinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berberine (chloride hydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the GSK1059615_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Temsirolimus_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sunitinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Elimusertib hydrochloride_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lactate (calcium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Elagolix sodium_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cloxacillin (sodium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Medroxyprogesterone acetate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dexamethasone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bortezomib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the RMC-6236_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bosentan (hydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ritonavir_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Megestrol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tucidinostat_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Regorafenib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Macitentan_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the APTO-253_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ERK5-IN-2_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Omeprazole (sodium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tucatinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sodium Salicylate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ivermectin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Allopurinol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cinacalcet_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belumosudil (mesylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pexidartinib (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Proglumide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Perindopril (erbumine)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Abiraterone acetate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Doxorubicin (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rucaparib (phosphate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 8-Hydroxyquinoline_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adenine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bisoprolol (hemifumarate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Benproperine (phosphate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Afatinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the palbociclib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Voriconazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aprepitant_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vilanterol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ribociclib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hexylresorcinol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methylthiouracil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bexarotene_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Loperamide (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Neratinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Resveratrol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Citalopram (hydrobromide)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bestatin (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Orlistat_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Imiquimod (maleate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LB-100_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Celecoxib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Volasertib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ouabain (Octahydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Posaconazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pemigatinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Docetaxel_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Triamcinolone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Norepinephrine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Omeprazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Darolutamide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clobetasol propionate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clopidogrel_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the SBI-0640756_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD1390_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gemfibrozil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Radotinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fingolimod (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clonidine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Amsacrine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clotrimazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the EX229_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bergenin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erdafitinib _Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trifluridine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belzutifan_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sinomenine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NG25_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the MK-3903_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Saquinavir_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the c-Kit-IN-1_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BI-78D3_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lidocaine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tubulin inhibitor 6_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ixazomib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Artemether_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Olanzapine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lumateperone (tosylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the γ-Oryzanol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Harringtonine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Panobinostat_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Budesonide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Betamethasone dipropionate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Baicalin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adenosine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trimetrexate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dabrafenib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Furosemide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lapatinib ditosylate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lucanthone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Almonertinib (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Imiquimod (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Finasteride_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the (S)-Crizotinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the DT-061_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Plicamycin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 5-Azacytidine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Verapamil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Capivasertib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Almonertinib (mesylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cytarabine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lopinavir_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methyl aminolevulinate (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pralsetinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Altretamine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Abemaciclib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 4EGI-1_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Asciminib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Eplerenone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentamidine (isethionate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rutin (trihydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the OTS514_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the PF-06260933_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Irinotecan (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Brivudine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tofacitinib (citrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Atazanavir (sulfate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Topotecan (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oxaprozin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vinblastine (sulfate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Indacaterol (maleate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mitoxantrone (dihydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dapagliflozin ((2S)-1,2-propanediol, hydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Acetazolamide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dorzolamide (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LJI308_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the olaparib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Malotilate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Captopril_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tirabrutinib (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Phenylephrine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fulvestrant_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Naproxen_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Econazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Niclosamide (olamine)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the S-Adenosyl-L-methionine (disulfate tosylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hesperidin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LY2090314_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Meloxicam_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sildenafil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Uridine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Darinaparsin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the PH-797804_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Carbamazepine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Carbidopa (monohydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Estrone sulfate (potassium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Busulfan_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Canagliflozin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Acetohexamide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rapamycin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 5-Fluorouracil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Thymopentin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tazarotene_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cepharanthine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cabozantinib (S-malate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Entrectinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mebendazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the IQ 1_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the vincristine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dinaciclib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dexmedetomidine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rimonabant_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Monocrotaline_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sapanisertib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Delamanid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the DTP3_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Levobupivacaine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Peretinoin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oxaliplatin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ETC-206_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ropivacaine (hydrochloride monohydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cilostazol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Balsalazide (sodium hydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Arbutin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Anethole trithione_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Artesunate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Riluzole hydrochloride_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Goserelin (acetate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Thymol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pasireotide (acetate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Decitabine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pyridoxine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Isocorydine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belumosudil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the CP21R7_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Piroxicam_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vortioxetine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Palmatine (chloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sonidegib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pimozide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Esmolol (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Infigratinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berbamine (dihydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Neratinib (maleate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Roxadustat_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ciclopirox_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Digitoxin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pimitespib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Entecavir (monohydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pioglitazone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Zileuton_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Brimonidine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tolmetin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Daidzin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Silodosin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Daptomycin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Menadione_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gemcitabine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tadalafil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Larotrectinib sulfate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ornidazole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Valdecoxib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rimonabant (Hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the L-Thyroxine (sodium salt pentahydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the MK-8353_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Doxycycline (monohydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clofarabine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Quinestrol_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vismodegib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Simotinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ranolazine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ligustrazine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Capmatinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gefitinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berbamine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dapagliflozin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Filgotinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cytarabine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cyclosporin A_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sulfatinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Phenytoin (sodium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mozavaptan_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fluvoxamine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Quinidine (15% dihydroquinidine)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fenofibrate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Apalutamide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belinostat_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erlotinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glasdegib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tirabrutinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the L-Eflornithine (monohydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nimesulide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pravastatin (sodium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sivelestat (sodium tetrahydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Selinexor _Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD-8055_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ML264_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Homoharringtonine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Edoxaban (tosylate monohydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Temuterkib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Torkinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tomivosertib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BAY1125976_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Diphenhydramine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Docetaxel (Trihydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methotrexate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Osimertinib (mesylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erythromycin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Flumatinib (mesylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aspirin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pyridoxine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Drospirenone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hydroxyurea_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bimatoprost_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Triclosan_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cysteamine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Azithromycin (hydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rifaximin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentagastrin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bicalutamide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vandetanib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Idoxuridine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Benztropine (mesylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tolcapone_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid (hydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ivabradine (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adagrasib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fedratinib (hydrochloride hydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lonafarnib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Crizotinib (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methylprednisolone succinate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fluvoxamine (maleate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LY-2584702 (tosylate salt)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Alpelisib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Procainamide (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Everolimus_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hydroxyfasudil_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Larotrectinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the TAK-901_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Flutamide_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dimethyl fumarate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ralimetinib dimesylate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ponatinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the venetoclax_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Irinotecan_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Futibatinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bentamapimod_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Chlorhexidine (diacetate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ipatasertib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Diammonium Glycyrrhizinate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pemetrexed_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentoxifylline_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bendamustine_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Canagliflozin (hemihydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Anastrozole_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BI-3406_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vemurafenib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Auranofin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD2858_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aliskiren_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tofacitinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Allantoin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nafamostat (mesylate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bestatin_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the crizotinib_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 9-ING-41_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Epirubicin (hydrochloride)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ataluren_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fostamatinib (disodium hexahydrate)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ixazomib citrate_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the HI-TOPK-032_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.